MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-10-2026
Exagen Retained Earnings 2011-2026 | XGN
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Exagen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -314 M | -294 M | -279 M | -256 M | -208 M | -181 M | -165 M | -153 M | -148 M | - | -108 M | -89.3 M | -74.3 M | -60.8 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -60.8 M | -314 M | -179 M |
Quarterly Retained Earnings Exagen
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -310 M | -303 M | -298 M | -294 M | -291 M | -286 M | -283 M | -279 M | -274 M | -268 M | -263 M | -256 M | -241 M | -233 M | -218 M | -208 M | -201 M | -194 M | -187 M | -181 M | -181 M | -181 M | -181 M | -165 M | -165 M | -165 M | -165 M | -153 M | -153 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -153 M | -310 M | -227 M |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
-2.23 B | $ 16.65 | -12.64 % | $ 179 M |  China |
|
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Castle Biosciences
CSTL
|
-200 M | $ 24.69 | - | $ 686 M |  USA |
 |
Agilent Technologies
A
|
348 M | $ 114.87 | - | $ 34.9 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | USA |
 |
Illumina
ILMN
|
-1.24 B | $ 126.92 | - | $ 20.2 B | USA |
 |
Aspira Women's Health
AWH
|
-544 M | - | -6.19 % | $ 10.5 M | USA |
 |
Lantheus Holdings
LNTH
|
680 M | $ 83.55 | - | $ 5.64 B | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-170 M | - | - | $ 9.42 M |  Israel |
 |
Co-Diagnostics
CODX
|
-80.4 M | $ 1.63 | - | $ 2.17 M | USA |
 |
Personalis
PSNL
|
-550 M | $ 5.5 | - | $ 326 M | USA |
 |
CareDx, Inc
CDNA
|
-735 M | $ 21.91 | - | $ 1.17 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
 |
Senseonics Holdings
SENS
|
-1.02 B | $ 7.18 | - | $ 300 M | USA |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-4.71 B | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
590 M | $ 15.3 | - | $ 463 M | USA |
 |
Trinity Biotech plc
TRIB
|
10.6 M | $ 0.61 | - | $ 61.9 M |  Irlanda |
 |
Twist Bioscience Corporation
TWST
|
-1.32 B | $ 59.15 | - | $ 3.54 B | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
1.39 B | $ 166.79 | 0.05 % | $ 8.27 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
Guardant Health
GH
|
-2.99 B | $ 83.09 | - | $ 10.4 B | USA |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
Interpace Biosciences
IDXG
|
-211 M | $ 1.93 | - | $ 8.54 M | USA |
 |
QIAGEN N.V.
QGEN
|
2.75 B | - | - | $ 10.6 B |  Niderland |
 |
Medpace Holdings
MEDP
|
-460 M | $ 409.65 | - | $ 11.8 B | USA |
 |
Biomerica
BMRA
|
-53.2 M | $ 2.18 | -0.46 % | $ 5.01 M | USA |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 102.49 | - | $ 8.45 B | Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 259.57 | - | $ 21.6 B | USA |
 |
NeoGenomics
NEO
|
-434 M | $ 9.02 | - | $ 1.16 B | USA |
 |
Celcuity
CELC
|
-449 M | $ 120.07 | - | $ 5.61 B | USA |
 |
Neogen Corporation
NEOG
|
-536 M | $ 9.34 | - | $ 2.03 B | USA |
 |
National Research Corporation
NRC
|
-17.3 M | $ 16.84 | -1.58 % | $ 377 M | USA |
 |
Myriad Genetics
MYGN
|
-1.12 B | $ 4.84 | - | $ 448 M | USA |
 |
Natera
NTRA
|
-1.94 B | $ 200.17 | - | $ 19.7 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.99 B | $ 195.05 | - | $ 21.7 B | USA |
 |
Invitae Corporation
NVTA
|
-4.83 B | - | - | $ 21.2 M | USA |
 |
OpGen
OPGN
|
-294 M | - | -16.95 % | $ 1.54 M | USA |